1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Thrombin

Thrombin

Thrombin is a Na+-activated, serine protease which is activated by the enzymatic cleavage of two sites on prothrombin by activated Factor X. Thrombin exists in two allosteric forms, slow (S) and fast (F), target toward anticoagulant and procoagulant activities.

Thrombin is the main effector protease in primary hemostasis by activating platelets and plays a key role in secondary hemostasis. Besides its well-known functions in hemostasis, thrombin also plays a role in various non-hemostatic biological and pathophysiologic processes, predominantly mediated through activation of protease-activated receptors (PARs). PAR-1, PAR-3, and PAR-4 are cleaved by thrombin, whereas PAR-2 is cleaved by trypsin. Thrombin also plays a crucial role in the migration and metastasis of human cancer cells.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10163S1
    Dabigatran-d3
    Inhibitor
    Dabigatran-d3 is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
    Dabigatran-d<sub>3</sub>
  • HY-P1741
    Fibrinogen-Binding Peptide
    99.83%
    Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin.
    Fibrinogen-Binding Peptide
  • HY-P0316A
    TP508 TFA
    Antagonist 99.44%
    TP508 TFA is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues.
    TP508 TFA
  • HY-129056
    Melagatran
    Inhibitor 99.31%
    Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia. Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion.
    Melagatran
  • HY-107966A
    Heparin calcium (MW 3600-5000)
    Inhibitor
    Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.
    Heparin calcium (MW 3600-5000)
  • HY-105069A
    Rusalatide acetate
    Ligand 98.14%
    Rusalatide acetate (TP508 amide acetate), a regenerative peptide, mitigates radiation-induced gastrointestinal damage by activating stem cells and preserving crypt integrity.
    Rusalatide acetate
  • HY-10217
    Thrombin Inhibitor 2
    Inhibitor 99.92%
    Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor, extracted from US8541580B2. Thrombin Inhibitor 2 has antithrombotic activity.
    Thrombin Inhibitor 2
  • HY-P2920
    Protamine from salmon
    Protamine from salmon is a biochemical agent with antioxidant, antiheparin and antimicrobial activities. Protamine from salmon neutralizes the anticoagulant effect of heparin, thereby preventing the formation of antithrombin complexes in canine samples pretreated with heparin in vitro.
    Protamine from salmon
  • HY-18660B
    Ciraparantag acetate
    Inhibitor ≥98.0%
    Ciraparantag (PER977) acetate is a thrombin and factor Xa inhibitor. Ciraparantag acetate is a broad-spectrum reversal agent for anticoagulants, including low molecular weight heparins, unfractionated heparins, and some direct oral anticoagulants, but not VKAs.
    Ciraparantag acetate
  • HY-129496
    NP-313
    Inhibitor 99.58%
    NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca2+ inward flow.
    NP-313
  • HY-P1921
    YRGDS Fibronectin Fragment
    98.86%
    YRGDS Fibronectin Fragment is a fibronectin fragment, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets.
    YRGDS Fibronectin Fragment
  • HY-10163AS
    Dabigatran-d4 hydrochloride
    Inhibitor ≥98.0%
    Dabigatran-d4 (hydrochloride) is deuterium labeled Dabigatran, which is a reversible and selective, direct thrombin inhibitor (DTI) with a Ki value of 4.5 nM.
    Dabigatran-d<sub>4</sub> hydrochloride
  • HY-P99465
    Befovacimab
    Inhibitor ≥99.0%
    Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research.
    Befovacimab
  • HY-10264A
    Edoxaban tosylate
    Inhibitor 99.84%
    Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research.
    Edoxaban tosylate
  • HY-B0375R
    Argatroban (Standard)
    Inhibitor
    Argatroban (Standard) is the analytical standard of Argatroban. This product is intended for research and analytical applications. Argatroban (MD-805) is a direct, selective thrombin inhibitor.
    Argatroban (Standard)
  • HY-10277
    Odiparcil
    Inhibitor 99.98%
    Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Odiparcil (SB-424323) is indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II) .
    Odiparcil
  • HY-10163S
    Dabigatran-d4
    Inhibitor
    Dabigatran-d4 is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
    Dabigatran-d<sub>4</sub>
  • HY-134686
    Edoxaban impurity 4
    Inhibitor 99.08%
    Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention.
    Edoxaban impurity 4
  • HY-10274S
    Dabigatran etexilate-d13
    Inhibitor 99.28%
    Dabigatran etexilate-d13 is the deuterium labeled Dabigatran etexilate. Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran. Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
    Dabigatran etexilate-d<sub>13</sub>
  • HY-W014134
    p-APMSF hydrochloride
    Inhibitor
    p-APMSF is an irreversible inhibitor of serinase. p-APMSF has substrate specificity for positively charged side chains of amino acids, lysine, or arginine. p-APMSF can be used to study the irreversible inhibition of trypsin and thrombin .
    p-APMSF hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity